2.09
price up icon2.70%   0.05
 
loading
Schlusskurs vom Vortag:
$2.04
Offen:
$2.05
24-Stunden-Volumen:
211.66K
Relative Volume:
1.56
Marktkapitalisierung:
$119.53M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-46.12M
KGV:
-2.7986
EPS:
-0.7468
Netto-Cashflow:
$-41.02M
1W Leistung:
+3.20%
1M Leistung:
+36.93%
6M Leistung:
+37.83%
1J Leistung:
+43.49%
1-Tages-Spanne:
Value
$1.97
$2.14
1-Wochen-Bereich:
Value
$1.51
$2.37
52-Wochen-Spanne:
Value
$1.165
$2.44

Inflarx N V Stock (IFRX) Company Profile

Name
Firmenname
Inflarx N V
Name
Telefon
-
Name
Adresse
-
Name
Mitarbeiter
66
Name
Twitter
Name
Nächster Verdiensttermin
2024-11-08
Name
Neueste SEC-Einreichungen
Name
IFRX's Discussions on Twitter

Vergleichen Sie IFRX mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
IFRX 2.095 119.53M 0 -46.12M -41.02M -0.7468
VRTX 450.62 115.43B 10.63B -479.80M -1.35B 13.33
REGN 749.43 82.04B 13.85B 4.65B 3.32B 35.06
ARGX 589.59 35.30B 1.86B -40.29M -1.28B -4.16
ALNY 247.12 32.04B 2.09B -332.26M 16.06M -4.14
BNTX 106.93 24.89B 3.30B -501.07M 1.03B 11.54

Inflarx N V Stock (IFRX) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2023-04-05 Hochstufung Guggenheim Neutral → Buy
2022-02-28 Herabstufung Guggenheim Buy → Neutral
2021-10-28 Hochstufung Raymond James Outperform → Strong Buy
2021-03-11 Hochstufung Guggenheim Neutral → Buy
2020-11-06 Hochstufung SVB Leerink Mkt Perform → Outperform
2020-10-08 Eingeleitet H.C. Wainwright Buy
2020-06-17 Eingeleitet BTIG Research Buy
2020-04-30 Hochstufung Raymond James Mkt Perform → Outperform
2019-06-05 Herabstufung BMO Capital Markets Outperform → Market Perform
2019-06-05 Herabstufung Guggenheim Buy → Neutral
2019-06-05 Herabstufung JP Morgan Overweight → Underweight
2019-06-05 Herabstufung Robert W. Baird Outperform → Neutral
2019-06-05 Herabstufung SunTrust Buy → Hold
2019-01-29 Eingeleitet Robert W. Baird Outperform
2018-12-10 Eingeleitet Credit Suisse Outperform
2018-07-13 Eingeleitet BMO Capital Markets Outperform
2018-06-28 Eingeleitet Raymond James Outperform
2018-06-28 Eingeleitet SunTrust Buy
2018-02-08 Eingeleitet B. Riley FBR, Inc. Buy
Alle ansehen

Inflarx N V Aktie (IFRX) Neueste Nachrichten

pulisher
Nov 19, 2024

10 Best German Stocks To Buy Now - Insider Monkey

Nov 19, 2024
pulisher
Nov 19, 2024

Is InflaRx N.V. (IFRX) the Best German Stock to Buy Now? - Yahoo Finance

Nov 19, 2024
pulisher
Nov 19, 2024

Lucid Capital sets Inflarx NV Buy stock rating on clinical trial potential - Investing.com

Nov 19, 2024
pulisher
Nov 15, 2024

InflaRx receives positive CHMP opinion for SARS-CoV-2-induced acute respiratory distress treatment - MSN

Nov 15, 2024
pulisher
Nov 15, 2024

InflaRx's GOHIBIC gets EMA panel nod for COVID-19 ARDS By Investing.com - Investing.com Canada

Nov 15, 2024
pulisher
Nov 15, 2024

InflaRx's GOHIBIC gets EMA panel nod for COVID-19 ARDS - Investing.com India

Nov 15, 2024
pulisher
Nov 15, 2024

InflaRx’s GOHIBIC gets EMA panel nod for COVID-19 ARDS By Investing.com - ழ தொலைக்காட்சி

Nov 15, 2024
pulisher
Nov 15, 2024

InflaRx Receives Positive CHMP Opinion for GOHIBIC® - GlobeNewswire

Nov 15, 2024
pulisher
Nov 15, 2024

InflaRx's GOHIBIC Secures Key EU Backing for COVID ARDS Treatment After 24% Mortality Reduction | IFRX Stock News - StockTitan

Nov 15, 2024
pulisher
Nov 15, 2024

FY2024 EPS Estimates for InflaRx Cut by Leerink Partnrs - Defense World

Nov 15, 2024
pulisher
Nov 14, 2024

U.S. Stock market top gainers: Omeros Corporation gains 52.99% while InflaRx N.V surges by 40.94% - Business Upturn

Nov 14, 2024
pulisher
Nov 14, 2024

FY2024 Earnings Forecast for InflaRx Issued By HC Wainwright - MarketBeat

Nov 14, 2024
pulisher
Nov 14, 2024

FY2024 EPS Estimates for InflaRx Reduced by Leerink Partnrs - MarketBeat

Nov 14, 2024
pulisher
Nov 13, 2024

Prenetics Global And 2 Other US Penny Stocks To Watch - Simply Wall St

Nov 13, 2024
pulisher
Nov 12, 2024

InflaRx Reports Q3 2024 Financial Results and Progress - Yahoo Finance

Nov 12, 2024
pulisher
Nov 11, 2024

InflaRx (NASDAQ:IFRX) Receives Buy Rating from HC Wainwright - MarketBeat

Nov 11, 2024
pulisher
Nov 10, 2024

We're A Little Worried About InflaRx's (NASDAQ:IFRX) Cash Burn Rate - Yahoo Finance

Nov 10, 2024
pulisher
Nov 08, 2024

InflaRx N.V. (IFRX) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance

Nov 08, 2024
pulisher
Nov 08, 2024

InflaRx Reports Rising Revenue Amidst Significant Losses - TipRanks

Nov 08, 2024
pulisher
Nov 08, 2024

InflaRx Reports Third Quarter 2024 Financial Results and Provides Business Update - GlobeNewswire

Nov 08, 2024
pulisher
Nov 07, 2024

InflaRx (IFRX) to Release Earnings on Friday - Defense World

Nov 07, 2024
pulisher
Nov 01, 2024

InflaRx (IFRX) Set to Announce Quarterly Earnings on Friday - MarketBeat

Nov 01, 2024
pulisher
Oct 31, 2024

InflaRx to Report Third Quarter 2024 Financial Results on November 8 and to Participate in Guggenheim Inaugural Healthcare Innovation Conference - The Manila Times

Oct 31, 2024
pulisher
Oct 31, 2024

InflaRx to Report Third Quarter 2024 Financial Results on - GlobeNewswire

Oct 31, 2024
pulisher
Oct 22, 2024

Critical Review: PDS Biotechnology (NASDAQ:PDSB) & InflaRx (NASDAQ:IFRX) - Defense World

Oct 22, 2024
pulisher
Oct 14, 2024

InflaRx (NASDAQ:IFRX) Sees Significant Increase in Short Interest - MarketBeat

Oct 14, 2024
pulisher
Sep 26, 2024

InflaRx shares maintain Buy rating from H.C. Wainwright on Gohibic trial analysis - Investing.com

Sep 26, 2024
pulisher
Sep 25, 2024

InflaRx (NASDAQ:IFRX) Given Buy Rating at HC Wainwright - Defense World

Sep 25, 2024
pulisher
Sep 25, 2024

InflaRx reports promising HS treatment results at EADV Congress - Investing.com India

Sep 25, 2024
pulisher
Sep 25, 2024

InflaRx (NASDAQ:IFRX) Given "Buy" Rating at HC Wainwright - MarketBeat

Sep 25, 2024
pulisher
Sep 25, 2024

InflaRx presents e-poster presentation of post hoc analysis of SHINE study - TipRanks

Sep 25, 2024
pulisher
Sep 25, 2024

InflaRx Presents Post Hoc Analysis of SHINE Trial of - GlobeNewswire

Sep 25, 2024
pulisher
Sep 25, 2024

InflaRx Presents Post Hoc Analysis of SHINE Trial of Vilobelimab in Hidradenitis Suppurativa at the 2024 - EIN News

Sep 25, 2024
pulisher
Sep 05, 2024

InflaRx Announces Participation in September Investor Events - Yahoo Finance UK

Sep 05, 2024
pulisher
Sep 05, 2024

InflaRx Presents New Preclinical Findings for INF904 at the 19th European Meeting on Complement in Human Diseases - Yahoo Finance UK

Sep 05, 2024
pulisher
Sep 04, 2024

InflaRx (NASDAQ:IFRX) Stock Price Up 1.3% - MarketBeat

Sep 04, 2024
pulisher
Sep 04, 2024

InflaRx (NASDAQ:IFRX) Shares Up 1.3% - Defense World

Sep 04, 2024
pulisher
Sep 03, 2024

InflaRx reports promising data on oral C5aR inhibitor INF904 - Investing.com

Sep 03, 2024
pulisher
Sep 03, 2024

InflaRx Presents New Preclinical Findings for INF904 at the 19th European Meeting on Complement in Human - EIN News

Sep 03, 2024
pulisher
Sep 03, 2024

InflaRx reports promising data on oral C5aR inhibitor INF904 By Investing.com - Investing.com UK

Sep 03, 2024
pulisher
Sep 03, 2024

InflaRx presents new preclinical findings for INF904 - TipRanks

Sep 03, 2024
pulisher
Sep 03, 2024

InflaRx Presents New Preclinical Findings for INF904 at the - GlobeNewswire

Sep 03, 2024
pulisher
Sep 01, 2024

InflaRx (NASDAQ:IFRX) Short Interest Down 9.2% in August - MarketBeat

Sep 01, 2024
pulisher
Aug 13, 2024

Short Interest in InflaRx (NASDAQ:IFRX) Rises By 281.4% - MarketBeat

Aug 13, 2024
pulisher
Aug 08, 2024

InflaRx N.V. (IFRX) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance

Aug 08, 2024
pulisher
Aug 08, 2024

InflaRx N.V. Reports Mid-Year Financial Results - TipRanks

Aug 08, 2024
pulisher
Aug 08, 2024

InflaRx Reports Second Quarter 2024 Financial Results and Provides Business Update - GlobeNewswire

Aug 08, 2024
pulisher
Aug 08, 2024

InflaRx reports Q2 EPS (24c), consensus (22c) - TipRanks

Aug 08, 2024
pulisher
Aug 07, 2024

InflaRx (IFRX) Set to Announce Earnings on Thursday - Defense World

Aug 07, 2024
pulisher
Aug 02, 2024

InflaRx (IFRX) to Release Earnings on Thursday - MarketBeat

Aug 02, 2024

Finanzdaten der Inflarx N V-Aktie (IFRX)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$18.98
price up icon 1.80%
$70.68
price down icon 0.42%
$38.38
price up icon 3.49%
$369.83
price up icon 1.48%
$196.58
price up icon 0.88%
$102.64
price up icon 0.27%
Kapitalisierung:     |  Volumen (24h):